

Valeria Patricia Sülsen  
Virginia Susana Martino  
*Editors*

# Sesquiterpene Lactones

Advances in their Chemistry  
and Biological Aspects

 Springer

# Sesquiterpene Lactones

Valeria Patricia Sülsen • Virginia Susana Martino  
Editors

# Sesquiterpene Lactones

Advances in their Chemistry  
and Biological Aspects

 Springer

*Editors*

Valeria Patricia Sülsen  
University of Buenos Aires  
CONICET University of Buenos Aires  
Autonomous City of Buenos Aires  
Buenos Aires, Argentina

Virginia Susana Martino  
University of Buenos Aires  
CONICET University of Buenos Aires  
Autonomous City of Buenos Aires  
Buenos Aires, Argentina

ISBN 978-3-319-78273-7      ISBN 978-3-319-78274-4 (eBook)  
<https://doi.org/10.1007/978-3-319-78274-4>

Library of Congress Control Number: 2018941468

© Springer International Publishing AG, part of Springer Nature 2018

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

*Cover illustration:* The image corresponds to the leaf surface of *Artemisia annua*, showing glandular trichomes, the site of artemisinin biosynthesis. The image belongs to The CNAP Artemisia Research Project, University of York, UK

Printed on acid-free paper

This Springer imprint is published by the registered company Springer International Publishing AG part of Springer Nature.

The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

*We wish to dedicate this book to our dear colleague, Argentine botanist Gustavo Carlos Giberti, who was the mentor of many Argentine medicinal flora scholars.*

*Gustavo Giberti, PhD (September 7th, 1951–July 2nd, 2017), graduated as Agricultural Engineer from University of Buenos Aires (UBA) in 1976.*

*He attended a postgraduate specialization course at Royal Botanic Gardens, Plant Anatomy Section (Kew, Great Britain), directed by David F. Cutler, PhD (1980–1982), and at Escuela Técnica Superior de Ingenieros Agrónomos, Universidad Politécnica de Madrid (Spain), directed by Prof. César Gómez Campo, PhD (1882–1983). In 2002, he earned a PhD from the University of Buenos Aires in the field of pharmacobotany and pharmacognosy.*

*From 1984 up to 2017, he worked as an Independent Researcher of the Scientific and Technological Research Career of the National Council for Scientific and Technical Research (CONICET) at Instituto de Química y Metabolismo del Fármaco*

*(Institute for Drug Chemistry and Metabolism Studies) (IQUIMEFA-UBA-CONICET), and as curator at the Herbarium of Museo de Farmacobotánica (Pharmacobotany Museum) “Juan Aníbal Domínguez” at the School of Pharmacy and Biochemistry (UBA). He also specialized in economic botany and pharmacobotany. In Argentina, he was an expert in plants of the Aquifoliaceae family, especially, those belonging to the Ilex genus.*

*He has authored more than forty scientific papers and about thirteen book chapters and also contributed largely by helping collect and identify the plant materials employed in the research works carried out at the IQUIMEFA.*

*We will always remember Gustavo for his gentleness and kindness and for his immense generosity to share his knowledge with all of us.*

# Foreword

This book was originally conceived as a smaller project focused only on the anti-parasitic activity of sesquiterpene lactones. After the evaluation of the proposal and taking into account the potential applications of this group of compounds, we decided to expand the scope and to explore chemical and biological aspects by including data on other biological activities and structure-activity studies.

Having obtained collaboration from renowned researchers in the field is, indeed, a dream come true. Virginia Martino, PhD, and César Catalan, PhD, deserve special mention, since they were my research directors and continue to be my mentors in the fields of pharmacognosy and chemistry, especially that of sesquiterpene lactones, respectively. Although they are both retired, they have given me support for the fulfillment of this project.

I am also grateful to those who have relied on and collaborated in this project: Marcus Tullius Scotti, PhD, and Fernando Batista da Costa, PhD (chemotaxonomy); Julián Rodríguez Talou, PhD, and María Perassolo, PhD (biotechnology); Francis Barrios, PhD (organic synthesis); Osvaldo Donadel, PhD (chemistry of natural products); Silvia Cazorla, PhD (trypanosomatids); Nubia Boechat, PhD (antiplasmodial compounds); María Elisa Lombardo, PhD (therapeutic targets and antitrypanosomal drugs); Miguel Sosa Escudero (microscopy); María Victoria Castelli, PhD, and Silvia Noelí López, PhD (antimicrobials); Claudia Anesini, PhD (antitumoral compounds); María Rosario Alonso, PhD (anti-inflammatory compounds); and Thomas J. Schmidt, Dr. rer. nat (structure-activity studies), who has given me access to Research Network Natural Products Against Neglected Diseases (ResNet NPND), which is devoted to the searching of novel natural drugs against neglected diseases.

Gustavo Giberti, PhD, also deserves a special mention in this Foreword. He has died unexpectedly in 2017 and to him we dedicate this book with all our affection. We will cherish in our hearts all the fieldwork and experiences we shared.

I believe the content of this book has met the goals. I would like to thank all the collaborating authors. As for me, I can only say: Mission accomplished!

Valeria P. Sülsen

# Preface

Although some interesting reviews on sesquiterpene lactones have been published, many advances have recently been made in this field, which implies the necessity of an update.

The aim of this book is to review such recent advances made in the study of sesquiterpene lactones, discussing their potential medical applications.

Different aspects will be reviewed, such as the distribution and taxonomy; the biosynthetic pathways; their chemistry, including the synthesis and chemical and biological transformations as well as the analytical isolation and identification procedures most frequently employed. Their biological properties mainly focused on the antimicrobial, antiproliferative, and anti-inflammatory activities and structure-activity studies will be also summarized. An update on the main molecular targets for their antiprotozoal activity will also be presented.

It is expected that this book will serve as a source of information to scientific researchers and postgraduate students, being inspiring for the performance of further studies on the chemistry and the biological activities of this fascinating group of compounds. Finally, the aim of this book is to highlight the importance of sesquiterpene lactones as lead molecules for the development of new therapeutic drugs.

Valeria P. Sülsen  
Virginia S. Martino

# Acknowledgments

We thank Dr. Luis Fernando de O. Furtado, Springer Science + Business Media Editor – Applied Sciences, for inviting us to participate in this editorial project and for believing that we could materialize it.

We also acknowledge Panneerselvam Silembarasan, the Project Coordinator (Books) for Springer Nature, for his guidance and prompt reply to our queries.

We are very grateful to all contributing authors for having embarked in this project and for sharing their knowledge and expertise, as well as for having devoted their time to compiling the literature material and to writing each chapter. We would like to congratulate them for the high quality of their contributions and their predisposition to revise the manuscripts.

We thank Guillermo Nuñez Taquíá, PhD, for English correction.

We kindly acknowledge Dr Caroline M. Calvert, CNAP Manager, HVCfP Network Manager, Department of Biology, University of York, York, UK, for providing the cover image.

We are profoundly thankful to the National Council for Scientific and Technical Research (CONICET), the University of Buenos Aires (UBA), and the National Agency for Scientific and Technological Promotion (ANPCyT) – Science, Technology and Productive Innovation Ministry for supporting this project.

This book entails a complex coordination of efforts and it is the embodiment of the work carried out by many people; we want to express our gratitude to all of them.

# Contents

## Part I Chemical and Biochemical Aspects of Sesquiterpene Lactones

<b>1 Overview</b> .....	3
Valeria P. Sülsen and Virginia S. Martino	
1.1 Introduction .....	4
1.2 Chemical Aspects .....	5
1.3 Some Representative Sesquiterpene Lactones .....	6
1.3.1 Santonin .....	6
1.3.2 Artemisinin .....	9
1.3.3 Parthenolide .....	9
1.3.4 Costunolide .....	9
1.3.5 Dehydroleucodine .....	10
1.3.6 Helenalin .....	10
1.3.7 Thapsigargin .....	10
1.3.8 Arglabin .....	11
1.3.9 Cynaropicrin .....	12
1.4 Adverse Health Effects and Toxicity of Sesquiterpene Lactones ..	12
References .....	13
<b>2 Ancient and Modern Concepts About the Asteraceae Taxonomy</b> ...	19
Gustavo C. Giberti	
2.1 Introduction .....	19
2.2 Asteraceae in Old Times Plant Systematics: Its Influences .....	20
2.3 Towards a “Contemporary” Asteraceae Systematics .....	23
2.4 Conclusion .....	25
References .....	26

<b>3</b>	<b>Chemotaxonomic Study of Sesquiterpene Lactones of Asteraceae: Classical and Modern Methods</b> . . . . .	31
	Mateus Feitosa Alves, Luciana Scotti, Fernando Batista Da Costa, and Marcus Tullius Scotti	
3.1	Introduction . . . . .	32
3.2	Classical Taxonomy . . . . .	33
3.3	Modern Chemotaxonomy . . . . .	36
3.4	Sesquiterpene Lactones Database . . . . .	39
3.5	Conclusion . . . . .	42
	References . . . . .	42
<b>4</b>	<b>Biosynthesis of Sesquiterpene Lactones in Plants and Metabolic Engineering for Their Biotechnological Production</b> . . . . .	47
	María Perassolo, Alejandra Beatriz Cardillo, Víctor Daniel Busto, Ana María Giulietti, and Julián Rodríguez Talou	
4.1	Introduction . . . . .	50
4.2	Biosynthesis of the Isoprenoid Precursors in Plants . . . . .	51
4.2.1	Mevalonate (MVA) Pathway . . . . .	51
4.2.2	2-C-Methyl-D-erythritol 4-phosphate (MEP) Pathway . . . . .	53
4.2.3	Cross-Talk Between MVA and MEP Pathways . . . . .	53
4.2.4	Farnesyl Diphosphate Synthase: Branch Point of Sesquiterpene Lactone Biosynthesis . . . . .	54
4.2.5	Sesquiterpene Lactone Pathway . . . . .	54
4.3	Sesquiterpene Lactone Biosynthetic Pathway Characterisation and Regulation in Medicinal and Aromatic Plants . . . . .	56
4.4	Biotechnological Approaches for the Production of Sesquiterpene Lactones: Plant Cell Culture . . . . .	62
4.5	Metabolic Engineering . . . . .	65
4.5.1	Metabolic Engineering in Plants and Plant Cell Culture . . . . .	66
4.5.2	Metabolic Engineering of the Artemisinin Biosynthetic Pathway . . . . .	67
4.6	Conclusion . . . . .	83
	References . . . . .	84
<b>5</b>	<b>Chemistry of Sesquiterpene Lactones</b> . . . . .	93
	Francis J. Barrios	
5.1	Synthesis of Sesquiterpene Lactones . . . . .	93
5.1.1	General Strategies for the Synthesis of the Germacranolide Skeleton . . . . .	94
5.1.2	Synthesis of the $\alpha$ -Methylene- $\gamma$ -Lactone Moiety . . . . .	94
5.1.3	Strategy to the Total Synthesis of Parthenolide . . . . .	96
5.1.4	Semi-synthesis of Parthenolide . . . . .	98
5.1.5	General Strategies for the Synthesis of Guaianolides . . . . .	99
5.1.6	Semi-synthesis of Guaianolides . . . . .	104
5.2	Chemical Transformation of Sesquiterpene Lactones . . . . .	108
5.2.1	Costunolide and Its Derivatives . . . . .	108

5.2.2	Parthenolide and Analogues . . . . .	109
5.2.3	Artemisinin and Its Derivatives . . . . .	111
5.2.4	Santonin and Its Analogues . . . . .	112
	References. . . . .	114
<b>6</b>	<b>Analytical Procedures. . . . .</b>	<b>119</b>
	Valeria P. Sülsen, Cesar A. N. Catalán, and Virginia S. Martino	
6.1	Structure of Sesquiterpene Lactones . . . . .	120
6.1.1	Skeletal Types of Sesquiterpene Lactones. . . . .	120
6.1.2	Common Side Chains in Sesquiterpene Lactones . . . . .	125
6.2	Extraction. . . . .	125
6.3	Isolation . . . . .	132
6.4	Chromatographic Analysis. . . . .	133
6.4.1	Thin Layer Chromatography . . . . .	133
6.4.2	High-Performance Liquid Chromatography . . . . .	134
6.4.3	Gas Chromatography . . . . .	134
6.5	Conclusion . . . . .	135
	References. . . . .	135
<b>7</b>	<b>Spectroscopic Methods for the Identification of Sesquiterpene Lactones . . . . .</b>	<b>137</b>
	Valeria P. Sülsen, Osvaldo J. Donadel, and Cesar A. N. Catalán	
7.1	General Spectroscopic Characteristics of Sesquiterpene Lactones . . . . .	137
7.1.1	MS Spectra. . . . .	138
7.1.2	IR Spectra. . . . .	139
7.1.3	UV Spectra. . . . .	139
7.1.4	CD Spectra. . . . .	140
7.1.5	NMR Spectra . . . . .	140
7.2	NMR Spectra of Sesquiterpene Lactones . . . . .	148
7.2.1	Guaianolides . . . . .	148
7.2.2	Pseudoguaianolides . . . . .	154
7.2.3	Eudesmanolides . . . . .	160
7.2.4	Germacranolides . . . . .	164
	References. . . . .	171
<b>Part II Biological Activities of Sesquiterpene Lactones</b>		
<b>8</b>	<b>Antitrypanosomal and Antileishmanial Activities . . . . .</b>	<b>175</b>
	Andrés Sánchez Alberti, Natacha Cerny, Augusto Bivona, and Silvia I. Cazorla	
8.1	Introduction to Neglected Tropical Diseases . . . . .	176
8.2	Chagas' Disease and Antitrypanosomal Activities of Sesquiterpene Lactones . . . . .	177
8.3	Leishmaniasis and Antileishmanial Activities of Sesquiterpene Lactones . . . . .	185

8.4	Human African Trypanosomiasis.....	190
8.5	Conclusion.....	192
	References.....	192
<b>9</b>	<b>Antiplasmodial Activity.....</b>	<b>197</b>
	Nubia Boechat, Luiz Carlos da Silva Pinheiro, and Flavia Fernandes da Silveira	
9.1	Introduction.....	198
	9.1.1 Malaria.....	198
	9.1.2 Current Chemotherapy for Malaria.....	199
9.2	Sesquiterpene Lactones as Antiplasmodial Agents.....	209
	9.2.1 Artemisinin and its Semisynthetic Derivatives.....	210
	9.2.2 Other Sesquiterpene Lactones with Antiplasmodial Activity.....	211
	9.2.3 Antimalarial Hybrids Containing Sesquiterpene Lactones.....	213
	9.2.4 Dimer, Trimer and Tetramer Sesquiterpene Lactones.....	216
9.3	Conclusion.....	217
	References.....	218
<b>10</b>	<b>Mode of Action on <i>Trypanosoma</i> and <i>Leishmania</i> spp.....</b>	<b>223</b>
	María E. Lombardo and Alcira Batlle	
10.1	Introduction.....	223
10.2	Molecular Targets.....	224
	10.2.1 Biosynthesis of Sterols.....	224
	10.2.2 Trypanothione Pathway.....	227
	10.2.3 Purine Salvage Pathway.....	228
	10.2.4 Cysteine Proteinases.....	229
	10.2.5 Trans-sialidase.....	230
	10.2.6 Tubulin.....	231
	10.2.7 Homeostasis of Calcium and Pyrophosphate Metabolism.....	231
	10.2.8 Uptake and Degradation of Heme.....	232
10.3	Oxidative Stress and Apoptosis.....	233
10.4	Natural Sesquiterpene Lactones: Parasitic Effects and Probable Targets in Trypanosomatids.....	234
	References.....	236
<b>11</b>	<b>Contribution of Microscopy for Understanding the Mechanism of Action Against Trypanosomatids.....</b>	<b>241</b>
	Esteban Lozano, Renata Spina, Patricia Barrera, Carlos Tonn, and Miguel A. Sosa	
11.1	Introduction.....	242
	11.1.1 Life Cycle of <i>Trypanosoma cruzi</i> .....	242
	11.1.2 Infection and Disease.....	242
	11.1.3 Morphology and Ultrastructure of <i>T. cruzi</i> .....	243

11.2	How Vulnerable Is <i>T. cruzi</i> ? . . . . .	250
11.2.1	Some Molecular Targets for Trypanocidal Agents . . . . .	250
11.3	In the Search for a Solution Against Parasitic Diseases. . . . .	252
11.3.1	Sesquiterpene Lactones . . . . .	253
11.3.2	Diterpenes . . . . .	253
11.3.3	Effect of Sesquiterpene Lactones and Diterpenes on <i>Trypanosoma cruzi</i> . . . . .	254
11.3.4	Effect of Sesquiterpene Lactones on <i>Leishmania</i> spp. . . . .	265
11.4	Conclusion . . . . .	269
	References. . . . .	269
<b>12</b>	<b>Effects on Other Microorganisms</b> . . . . .	<b>275</b>
	María Victoria Castelli and Silvia Noélf López	
12.1	Introduction . . . . .	276
12.2	Antifungal, Antibacterial, and Antiviral Activity. . . . .	277
12.2.1	Guaianolides and Pseudoguaianolides. . . . .	277
12.2.2	Eudesmanolides . . . . .	281
12.2.3	Germacranolides and Other Related Structures. . . . .	286
12.2.4	Carabranolides . . . . .	292
12.2.5	Dimeric Sesquiterpene Lactones . . . . .	293
12.2.6	Seco-prezizaane Sesquiterpene Lactones . . . . .	295
12.2.7	Cadinanolides . . . . .	296
12.2.8	Microbial Sesquiterpene Lactones. . . . .	297
12.3	Conclusion . . . . .	298
	References. . . . .	299
<b>13</b>	<b>Antiproliferative and Cytotoxic Activities</b> . . . . .	<b>303</b>
	Claudia A. Anesini, María Rosario Alonso, and Renzo F. Martino	
13.1	Introduction . . . . .	306
13.2	In Vitro Studies and Mechanism of Action . . . . .	309
13.3	In Vivo Studies . . . . .	315
13.4	Clinical Trials. . . . .	317
13.5	Conclusion . . . . .	319
	References. . . . .	319
<b>14</b>	<b>Anti-inflammatory Activity</b> . . . . .	<b>325</b>
	María Rosario Alonso, Claudia A. Anesini, and Renzo F. Martino	
14.1	Introduction . . . . .	327
14.2	Inflammatory Pathways Serving as Pharmacological Targets in Inflammatory Diseases. . . . .	328
14.2.1	Inflammatory Cytokines . . . . .	329
14.2.2	Caspase-1 and the Inflammasome Complex Nod-Like Receptor Family Pyrin Domain Containing the Complex NLRP3 . . . . .	331
14.2.3	Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells. . . . .	332

14.2.4	The Janus Kinase (Jak)/Signal Transducers and Activators of Transcription (STATs) Pathway . . . . .	332
14.2.5	Nitric Oxide . . . . .	333
14.2.6	Reactive Oxygen Species. . . . .	333
14.2.7	Mitogen-Activated Protein Kinases. . . . .	334
14.2.8	Lipid Mediators . . . . .	334
14.3	Which Are the Most Currently Used Drugs to Treat Inflammation?. . . . .	335
14.4	Effects of Sesquiterpene Lactones on Inflammatory Pathways . . . . .	338
14.4.1	Effects on the NF- $\kappa$ B Pathway . . . . .	338
14.4.2	Effects on Janus Kinase (Jak)/Signal Transducers and Activators of Transcription (STATs) Pathway . . . . .	340
14.4.3	Effects on Cytokine Production, Maturation, and Release . . . . .	340
14.4.4	Effect on Nitric Oxide, Reactive Oxygen Species, Reactive Nitrogen Species, and Antioxidant Contents. . . . .	341
14.4.5	Effect on the Production of Lipid Mediators. . . . .	341
14.4.6	Effects on Mitogen-Activated Protein Kinase. . . . .	342
14.5	Conclusion . . . . .	342
	References. . . . .	343

### Part III Sesquiterpene Lactones: Medicinal Chemistry Approach

<b>15</b>	<b>Structure-Activity and Activity-Activity Relationships of Sesquiterpene Lactones . . . . .</b>	<b>349</b>
	Thomas J. Schmidt	
15.1	Introduction . . . . .	350
15.2	Structure-Antiprotozoal Activity Relationships. . . . .	350
15.2.1	Anti-trypanosomatid Activity: <i>Trypanosoma brucei</i> . . . . .	350
15.2.2	Anti-trypanosomatid Activity: <i>Trypanosoma cruzi</i> . . . . .	357
15.2.3	Anti-trypanosomatid Activity: <i>Leishmania</i> Species . . . . .	359
15.2.4	Antiplasmodial Activity and SAR (Excluding Artemisinin and Derivatives) . . . . .	360
15.3	Structure-Antitumor Activity Relationships . . . . .	362
15.4	Structure-Anti-inflammatory Activity Relationship. . . . .	367
15.5	Conclusion . . . . .	368
	References. . . . .	369

# Contributors

**Andrés Sánchez Alberti** Cátedra de Inmunología, IDEHU (UBA-CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina

Instituto de Microbiología y Parasitología Médica, IMPaM (UBA-CONICET), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina

**María Rosario Alonso** Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Farmacología, Cátedra de Farmacología, Buenos Aires, Argentina

CONICET – Universidad de Buenos Aires, Instituto de Química y Metabolismo del Fármaco (IQUIMEFA), Buenos Aires, Argentina

**Mateus Feitosa Alves** Federal University of Paraíba, João Pessoa, PB, Brazil

**Claudia A. Anesini** CONICET – Universidad de Buenos Aires, Instituto de Química y Metabolismo del Fármaco (IQUIMEFA), Buenos Aires, Argentina

Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Farmacología, Cátedra de Farmacognosia, Buenos Aires, Argentina

**Patricia Barrera** Laboratorio de Biología y Fisiología Celular Dr. Francisco Bertini, Instituto de Histología y Embriología (IHEM-CONICET), Mendoza, Argentina

**Francis J. Barrios** Department of Chemistry and Physics, Bellarmine University, Louisville, KY, USA

**Alcira Batlle** CONICET – Universidad de Buenos Aires, Centro de Investigaciones sobre Porfirinas y Porfirias (CIPYP), Buenos Aires, Argentina

**Augusto Bivona** Cátedra de Inmunología, IDEHU (UBA-CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina

Instituto de Microbiología y Parasitología Médica, IMPaM (UBA-CONICET), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina

**Nubia Boechat** Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos Farmanguinhos-Fiocruz, Rio de Janeiro, Brazil

**Víctor Daniel Busto** Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Microbiología, Inmunología y Biotecnología, Cátedra de Biotecnología, Buenos Aires, Argentina

CONICET-Universidad de Buenos Aires, Instituto de Nanobiotecnología (NANOBIOTEC), Buenos Aires, Argentina

**Alejandra Beatriz Cardillo** Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Microbiología, Inmunología y Biotecnología, Cátedra de Biotecnología, Buenos Aires, Argentina

CONICET-Universidad de Buenos Aires, Instituto de Nanobiotecnología (NANOBIOTEC), Buenos Aires, Argentina

**María Victoria Castelli** Farmacognosia –Facultad de Ciencias Bioquímicas y Farmacéuticas – CONICET – Universidad Nacional de Rosario, Rosario, Argentina

**Cesar A. N. Catalán** CONICET – Universidad Nacional de Tucumán, Instituto de Química del Noroeste – CONICET (INQUINOA), San Miguel de Tucumán, Argentina

**Silvia I. Cazorla** Laboratorio de Inmunología, Centro de Referencia para Lactobacilos (CERELA-CONICET), Tucumán, Argentina

Instituto de Microbiología y Parasitología Médica, IMPaM (UBA-CONICET), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina

**Natacha Cerny** Cátedra de Inmunología, IDEHU (UBA-CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina

Instituto de Microbiología y Parasitología Médica, IMPaM (UBA-CONICET), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina

**Fernando Batista Da Costa** AsterBioChem Research Team, University of São Paulo, School of Pharmaceutical Sciences of Ribeirao Preto, Ribeirao Preto, SP, Brazil

**Luiz Carlos da Silva Pinheiro** Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos Farmanguinhos-Fiocruz, Rio de Janeiro, Brazil

**Flavia Fernandes da Silveira** Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos Farmanguinhos-Fiocruz, Rio de Janeiro, Brazil

Programa de Pós-graduação em Química da Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

**Oswaldo J. Donadel** Instituto de Investigaciones en Tecnología Química (INTEQUI), Universidad Nacional de San Luis, San Luis, Argentina

**Gustavo C. Giberti** Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina

CONICET – Universidad de Buenos Aires. Instituto de Química y Metabolismo del Fármaco – CONICET (IQUIMEFA), Buenos Aires, Argentina

**Ana María Giulietti** CONICET-Universidad de Buenos Aires, Instituto de Nanobiotecnología (NANOBIOTEC), Buenos Aires, Argentina

**María E. Lombardo** Universidad de Buenos Aires, Facultad de Ciencias Exactas y Naturales, Departamento de Química Biológica, Buenos Aires, Argentina

CONICET – Universidad de Buenos Aires, Centro de Investigaciones sobre Porfirinas y Porfirias (CIPYP), Buenos Aires, Argentina

**Silvia Noelí López** Farmacognosia – Facultad de Ciencias Bioquímicas y Farmacéuticas – CONICET – Universidad Nacional de Rosario, Rosario, Argentina

**Esteban Lozano** Laboratorio de Inmunología y Desarrollo de Vacunas, Instituto de Medicina y Biología Experimental de Cuyo (IMBECU, CCT-CONICET), Mendoza, Argentina

**Renzo F. Martino** Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Microbiología, Inmunología y Biotecnología. Cátedra de Inmunología, Buenos Aires, Argentina

**Virginia S. Martino** CONICET – Universidad de Buenos Aires, Instituto de Química y Metabolismo del Fármaco – CONICET (IQUIMEFA), Buenos Aires, Argentina

**María Perassolo** Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Microbiología, Inmunología y Biotecnología, Cátedra de Biotecnología, Buenos Aires, Argentina

CONICET-Universidad de Buenos Aires, Instituto de Nanobiotecnología (NANOBIOTEC), Buenos Aires, Argentina

**Thomas J. Schmidt** Institute of Pharmaceutical Biology and Phytochemistry (IPBP), University of Münster, PharmaCampus, Münster, Germany

**Luciana Scotti** Federal University of Paraíba, João Pessoa, PB, Brazil

**Marcus Tullius Scotti** Federal University of Paraíba, João Pessoa, PB, Brazil

**Miguel A. Sosa** Laboratorio de Biología y Fisiología Celular Dr. Francisco Bertini, Instituto de Histología y Embriología (IHEM-CONICET), Mendoza, Argentina

**Renata Spina** Laboratorio de Biología y Fisiología Celular Dr. Francisco Bertini, Instituto de Histología y Embriología (IHEM-CONICET), Mendoza, Argentina

**Valeria P. Sülsen** Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Farmacognosia, Buenos Aires, Argentina

CONICET – Universidad de Buenos Aires, Instituto de Química y Metabolismo del Fármaco – CONICET (IQUIMEFA), Buenos Aires, Argentina

**Julián Rodríguez Talou** Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Microbiología, Inmunología y Biotecnología, Cátedra de Biotecnología, Buenos Aires, Argentina

CONICET-Universidad de Buenos Aires, Instituto de Nanobiotecnología (NANOBIOTEC), Buenos Aires, Argentina

**Carlos Tonn** Instituto de Investigación en Tecnología Química (INTEQUI), Facultad de Química Bioquímica y Farmacia, Universidad Nacional de San Luis, San Luis, Argentina

**Part I**  
**Chemical and Biochemical Aspects of**  
**Sesquiterpene Lactones**

# Chapter 1

## Overview



Valeria P. Sülsen and Virginia S. Martino

**Abstract** Sesquiterpene lactones (STLs) are a group of naturally occurring compounds, most of them found in the Asteraceae family but also present in Apiaceae, Magnoliaceae, and Lauraceae. To date about 8000 compounds have been reported. They consist of a C15 backbone with numerous modifications resulting in a variety of structures but with the common feature of a  $\gamma$ -lactone ring. They are classified in four major groups: germacranolides, eudesmanolides, guaianolides, and pseudoguaianolides, though there are other subtypes. There has been an increasing interest in sesquiterpene lactones due to the wide range of biological activities they present. Among the activities found, antimicrobial, antitumor, anti-inflammatory, antioxidant, antiulcerogenic, molluscicidal, antihelminthic, hepatoprotective and hepatotherapeutic, antiprotozoal, antidepressant, and bitter properties have been described. Besides, they play an important role in the interaction of plants with insects acting as attractants, deterrents, and antifeedants. These compounds were considered at first highly cytotoxic, but chemical transformations have enhanced their biological activities and diminished their cytotoxicity, so considerable attention has been drawn again on them as lead molecules. Artemisinin derivatives, artesunate, and artemether are drugs currently being employed, and dimethylaminoparthenolide, a parthenolide synthetic analogue, and mipsagargin, a prodrug from thapsigargin, are under clinical trials.

A summary with the most important findings about the known sesquiterpene lactones, artemisinin, parthenolide, cynaropicrin, dehydroleucodine, mexicanin, helenalin, costunolide, santonin, arglabin, and thapsigargin, will be given.

---

V. P. Sülsen (✉)

Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Farmacognosia, Buenos Aires, Argentina

CONICET – Universidad de Buenos Aires. Instituto de Química y Metabolismo del Fármaco - CONICET (IQUIMEFA), Buenos Aires, Argentina

e-mail: [vsulsen@ffyb.uba.ar](mailto:vsulsen@ffyb.uba.ar)

V. S. Martino

CONICET – Universidad de Buenos Aires. Instituto de Química y Metabolismo del Fármaco – CONICET (IQUIMEFA), Buenos Aires, Argentina

Studies about the adverse health effects, toxicity, and ecological roles of some sesquiterpene lactones are also mentioned.

**Keywords** Sesquiterpene lactones · Chemical aspects · Biological activities · Adverse effects · Toxicity

## 1.1 Introduction

Since ancient times, natural products have played an important role in human health and have constituted one of the main sources of bioactive compounds and templates for synthetic modifications. According to Newman and Cragg (2016), the utilization of natural products and their derivatives in the development of new therapeutic drugs is still a promising approach. Recently, the 2015 Nobel Prize in Medicine has been awarded to Dr. Youyou Tu for the discovery of the natural product artemisinin, which is today an important component of the combined therapy for the treatment of malaria. This award highlighted the importance of the investigation of traditional medicine and drugs coming from natural sources (The Society for Medicinal Plant and Natural Product Research 2017). In the cancer research field, during the 1940–2014 period, 49% of all the small molecules approved for medical use were natural products or their derivatives. In other areas, such as the one corresponding to antimicrobial agents, the use of natural products is also frequent.

Sesquiterpene lactones (STLs) are a group of naturally occurring compounds, generally colorless and bitter in taste. Most of them are found in the Asteraceae family; however, they are also present in Apiaceae, Magnoliaceae, and Lauraceae families (Padilla González et al. 2016). They are mainly found in the leaves and in the flowering heads in a range from 0.001% to 8%/dry weight (Chaturvedi 2011). Some species store large amounts of STLs in leaf trichomes (Amorim et al. 2013).

Sesquiterpene lactones are present in food plants such as lettuce (*Lactuca sativa*) and chicory (*Cichorium intybus*), and star anise (*Illicium verum*) and in many medicinal plants such as feverfew (*Tanacetum parthenium*), qinghaosu (*Artemisia annua*), and yarrow (*Achillea* spp.) (Chaturvedi 2011).

There has been an increasing interest in STLs, mainly for their importance as chemical markers in biosystematic studies and for their wide range of biological activities. Among the activities explored for this group of compounds, antimicrobial, antitumor, anti-inflammatory, antioxidant, antiulcerogenic, molluscicidal, anti-helminthic, hepatoprotective and hepatotherapeutic, antidepressant, and bitter properties have been described. Besides, they play an important role in the interaction of plants with insects acting as attractants, deterrents, and antifeedants (Chaturvedi 2011; Amorim et al. 2013).

Sesquiterpene lactones were considered at first highly cytotoxic. Chemical transformations have enhanced their biological activities and diminished their cytotoxicity, so considerable attention has been drawn again on them as lead molecules.

Artemisinin derivatives, artesunate, and artemether are drugs currently being employed, and dimethylaminoparthenolide, a parthenolide synthetic analogue, and mipsagargin, a prodrug from thapsigargin, are under clinical trials.

To date, about 8000 STLs have been reported (Macias et al. 2013). Some early reviews can be found in the literature about STLs which can be considered as a starting point for the present overview. In Yoshioka et al. (1973), the major skeleton types of STLs and the NMR spectra of 200 naturally occurring compounds are presented. Fischer et al. (1979) and Fischer (1990) summarize the biogenetic considerations concerning the different types of STLs as well as the regulation of their biosynthetic pathways. Rodriguez et al. (1976) and Picman (1986) disclose and discuss some of the more important biological activities of STLs. Other more recent reviews by Chaturvedi (2011) describe the structural characteristics and the biological activities of these compounds, while Chadwick et al. (2013) highlight the importance of STLs, not only for their potential as pharmaceutical agents but also for their importance as nutritional factors and for their physiological role in plants as antioxidants and growth factors, antifeedants, and allelochemicals and as the active constituents of many plants used in traditional medicine. Adekenov (2013) provides an overview of the available technology for the isolation of natural STLs and the chemical modifications to which STLs can be subjected and discusses their potential as source of new biologically active derivatives. In a subsequent publication, Adekenov and Atazhanova (2013) summarize the heteroatom-containing natural STLs, their natural occurrence, isolation methods, and biological activities, while Hohmann et al. (2016) disclose their anti-inflammatory effects. Padilla González et al. (2016) discuss the protective and physiological role of STLs in plants.


## 1.2 Chemical Aspects

Sesquiterpene lactones consist of a fifteen-carbon (C15) backbone, being the majority cyclic, with numerous modifications and resulting in a variety of structures. A distinctive feature of STLs is the presence of a  $\gamma$ -lactone ring closed toward either C-6 or C-8. This  $\gamma$ -lactone contains, in many cases, an *exo*-methylene group conjugated to the carbonyl group (Padilla González et al. 2016; Picman 1986). The stereochemistry of the lactonization can be either  $\alpha$  or  $\beta$ , since the lactone ring can be fused to the remaining skeleton in either a *trans* or *cis* configuration (*trans*- or *cis*-fused STLs) (Padilla González et al. 2016; Ahern and Whitney 2014). The *trans*-configuration is the most common, and as a rule, the H-7 of STLs is  $\alpha$ -oriented (Fischer 1990) (Fig. 1.1).

In some STLs, the exocyclic methylene is reduced, as is the case of artemisinin, matricin, achillin, and santonin, or the double bond can be endocyclic (Padilla González et al. 2016).

Sesquiterpene lactones are classified in four major groups: germacranolides (10-membered ring), eudesmanolides (6–6 bicyclic compounds), guaianolides, and pseudoguaianolides (5–7 bicyclic compounds) (Yoshioka et al. 1973) (Fig. 1.2). Nevertheless, according to their skeletal arrangement, there are other subtypes of

**Fig. 1.1**  $\alpha,\beta$ -unsaturated  $\gamma$ -lactone moiety present in the sesquiterpene lactones. (a) *trans*-fused lactone ring, (b) *cis*-fused lactone ring







STLs (Fischer et al. 1979; Rodriguez et al. 1976; Picman 1986; Padilla Gonzalez et al. 2016). The suffix “olide” indicates the presence of a lactone group in the structure. The presence of epoxy groups, hydroxyls, and hydroxyls esterified with acetate, which is the most frequent, propionate, isobutyrate, methacrylate, isovalerate, epoxymethacrylate, 2-methylbutanoate, tiglate, angelate, senecioate, epoxyangelate, sarracinate, acetylsarracinate, and other similar residues is frequently found in STLs. Only a few glycosylated lactones or lactones bearing halogen or sulfur atoms in their structures have been described. A cyclopentenone moiety (dehydroleucodin, achillin) and a second  $\alpha,\beta$ -unsaturated lactone ring (mikanolide, deoxyelephantopin) can also be found in STLs (Rodriguez et al. 1976; Picman 1986; Schmidt et al. 2002).

### 1.3 Some Representative Sesquiterpene Lactones

The STLs included in this chapter have been selected based upon the number of studies found in the literature, their biological activities, and/or the fact they are actually being used as medicines or are in clinical trials (Fig. 1.3).

#### 1.3.1 Santonin

Santonin (**1**) is an eudesmanolide present in *Artemisia santonica* and is one of the earliest STLs discovered (1830). This STL has been used as ascaricide and to remove all kind of worms and for the retention of urine and enuresis caused by atony or of other origins. Its pharmaceutical use was abandoned due to its toxic effects. Its anti-inflammatory, antipyretic, and analgesic effects have been reported (al-Harbi et al. 1994). Numerous chemical modifications have been introduced on the santonin structure in order to enhance its antiproliferative activity and cell differentiation on leukemia cells (Khazir et al. 2013; Kweon et al. 2011; Arantes et al. 2010) and its antimalarial activity (Tani et al. 1985). This molecule has been selected as the starting point for the synthesis of other guaianolides and eudesmanolides. Its structure was one of the first to be elucidated among STLs (Birladeanu 2003).

**Germacranolides****Guaianolides****Pseudoguaianolides****Eudesmanolides****Fig. 1.2** Major skeletal types of sesquiterpene lactones




Fig. 1.3 Some representative sesquiterpene lactones

### 1.3.2 Artemisinin

Artemisinin (**2**) is a very particular compound, for it presents an endoperoxide ring in its molecular structure. This STL has been isolated from *Artemisia annua* (Asteraceae). The aerial parts of this plant have been used as febrifuge in Chinese traditional medicine. Nowadays artemisinin and its derivatives are used as antimalarial against chloroquine-resistant *Plasmodium falciparum*. Other activities reported for this STL include leishmanicidal (Lezama Dávila et al. 2007; Ghaffarifar et al. 2015) and anticancer. The latter property is due to its capacity to inhibit cell growth and to induce apoptosis in human hepatocellular carcinoma cells (SMMC-7721) (Deng et al. 2013) and other cell lines (Crespo Ortiz and Wei 2012; Das 2015). Artemisinin also shows antischistosomal activity (Saed et al. 2016). Activity against *Helicobacter pylori* has also been reported (Sisto et al. 2016).

Artemisinin derivatives are currently being assessed in phase I and II trials against lupus nephritis and breast, colorectal, and lung cancers (Lone et al. 2015).

### 1.3.3 Parthenolide

Parthenolide (**3**) is the active principle of feverfew (*Tanacetum parthenium*, Asteraceae). It is a traditional herbal medicine that has been used for centuries for the treatment of migraine, fever, and arthritis (Chaturvedi 2011). This STL has antiproliferative activity on multiple cancer cells such as melanoma; breast, colon, and lung cancer; and leukemia, among others (Wu et al. 2006; Parada Turska et al. 2007; Czyz et al. 2010; Gunn et al. 2011, Mathema et al. 2012). The compound selectivity to exert apoptosis in cancer cells provides an important and novel therapeutic strategy for the treatment of cancer and inflammation-related disorders (Liu 2013).

Other activities have been described for parthenolide such as antiprotozoal (against *Trypanosoma cruzi* and *Leishmania* spp.) (Izumi et al. 2008; Tiunan et al. 2005), anti-inflammatory (Wang and Li 2015), antiherpetic (Onozato et al. 2009), and antiosteoclastogenic (Kim et al. 2014).

### 1.3.4 Costunolide

Costunolide (**4**) is a germacranolide-type STL present in *Saussurea lappa* roots, a traditional Chinese medicinal herb that has anticancer and anti-inflammatory properties. This compound has also been isolated from other plant species such as *Magnolia* sp., *Laurus nobilis*, and *Costus speciosus*, among others. It exhibits a broad spectrum of bioactivities: antidiabetic and antioxidant (Eliza et al. 2009, 2010), anti-inflammatory (Butturini et al. 2014), antiulcerogenic (Zheng et al. 2016), anticlastogenic

(Cheon et al. 2014), and potential anticancer activity. Costunolide exerts its antiproliferative effect by inducing apoptosis through ROS generation (Wang et al. 2016) and cell cycle arrest (Liu et al. 2011; Lin et al. 2016), among other mechanisms. This STL is active on lung carcinoma (Wang et al. 2016; Hua et al. 2016); breast (Roy and Manikkam 2015), colon (Dong et al. 2015), bladder (Rasul et al. 2013), and platinum-resistant ovarian cancer (Yang et al. 2011); hepatoma (Liu et al. 2011); and leukemic (Choi and Lee 2009) cells.

### 1.3.5 *Dehydroleucodine*

Dehydroleucodine (**5**) is a STL isolated from *Artemisia douglasiana* which shows cytotoxic activity against human leukemia cells (Ordoñez et al. 2016) and inhibits the growth of melanoma cells in an animal model (Costantino et al. 2016). It reduces inflammation and gastrointestinal ethanol-induced damage, protecting the gastric mucosa, as demonstrated in in vivo models (Guardia et al. 2003; Wendel et al. 2008; Repetto and Boveris 2010). This compound has inhibitory effect on *T. cruzi* infective forms and *Leishmania mexicana* promastigotes (Jimenez Ortiz et al. 2005; Barrera et al. 2008). Antimicrobial activity against *Pseudomonas aeruginosa* multiresistant strains has also been reported for this compound (Mustafi et al. 2015).

### 1.3.6 *Helenalin*

Helenalin (**6**) is a guaianolide STL isolated from *Arnica montana* and other species of the Asteraceae family. It has been reported to possess cytotoxic (Grippio et al. 1992), hepatoprotective, anti-inflammatory, antioxidant (Lin et al. 2014), and antimicrobial properties against *Staphylococcus aureus* (Boulanger et al. 2007). It affects steroidogenesis in rat adrenocortical cells (Supornsilchai et al. 2006) and has cardiogenic activity (Itoigawa et al. 1987). Trypanocidal effects have also been reported (Schmidt et al. 2002; Jimenez-Ortiz et al. 2005).

### 1.3.7 *Thapsigargin*

Thapsigargin (**7**) is a guaianolide STL isolated from *Thapsia garganica* (Apiaceae). This Mediterranean medicinal plant was mentioned by Hippocrates, Theophrastus, Dioscorides, and Plinius as skin irritant, useful for pulmonary disease, catarrh, and fever and for the relief of rheumatic pains. In search for the skin-irritant principle, thapsigargin was isolated from the fruits and roots, and its structure and absolute configuration were determined between 1980 and 1985. This compound proved to be a potent histamine liberator and a cocarcinogen promoting skin cancer in mice

(Anderson et al. 2016). Nevertheless, the increasing interest in thapsigargin arose with the discovery of its ability to inhibit the sarco-endoplasmic reticulum calcium ATPase (SERCA) pump. The inhibition of this pump produces a high concentration of calcium in the cytosol, which leads to apoptosis. Several analogues have been obtained from thapsigargin, and a prodrug, termed mipsagargin, has been designed. Mipsagargin has shown an acceptable tolerability and a favorable pharmacokinetic profile in patients with solid tumors. Phase I clinical trials have been completed (Mahalingam et al. 2016). This compound has been authorized by the FDA to enter phase II clinical trials on patients suffering from hepatocellular carcinoma who had failed the first-line treatment with sorafenib and also on patients suffering from glioblastoma (Nhu and Christensen 2015). Inspyr Therapeutics Inc. (Texas, USA) has announced the initiation of a phase II clinical trial of mipsagargin for newly diagnosed prostate cancer patients (Inspyr 2016).

### 1.3.8 Arglabin

Arglabin (**8**) is a STL of the guaianolide type isolated for the first time by Adekenov et al. (1982) from *Artemisia glabella*, which is a plant species growing in Kazakhstan. It is present in the above ground parts (leaves, bud flowers, and stems). Later on, arglabin has been reported to be present in *A. myriantha* (Wong and Brown 2002), which is a well-known plant used in Chinese traditional medicine.

Arglabin shows promising antitumor activity against different tumor cell lines. Many derivatives have been obtained, and those bearing bromine and chlorine atoms and an epoxy group on the C(3)=C(4) double bond seem to have an increased antitumor activity. Dimethylamino arglabin, one of these derivatives, has been used to treat lung, liver, and ovarian cancers and is under study in phase I and II clinical trials (Lone et al. 2015). This STL has been patented in the USA and has been registered as an antitumor medicine in the Russian Federation, Kazakhstan, Uzbekistan, Tajikistan, the Kirghiz Republic, and Georgia (Adekenov 2016).

Arglabin acts as antitumor by a different mechanism from artemisinin, thapsigargin derivative, and parthenolide. It inhibits the farnesyl transferase, which is an enzyme that has been demonstrated to be involved in the formation of malignant tumors. Besides, this compound shows other biological activities: it has an inhibitory effect on influenza A virus, it can restore the synthesis of cytokines and other anti-inflammatory mediators acting as anti-inflammatory in in vivo models of inflammation (carrageenan, histamine, and formalin models), and it has immunomodulatory activity (Lone et al. 2015). Abderrazak et al. (2016) have demonstrated that arglabin reduces inflammation in pancreatic  $\beta$ -cells in vivo and in the INS-1 cell line in vitro, thus concluding that it may represent a new promising compound to treat inflammation and type 2 diabetes mellitus.